

Development of New Reference Material for Biopharmaceutical Advancement

Srivalli Telikepalli, Ph.D.
Biomolecular Measurement Division
National Institute of Standards & Technology

CASSS – Consultant's Network
March 23, 2026

Disclaimer

Certain commercial equipment, instruments, or materials may be identified in this presentation to specify the experimental procedure. Such identification is not intended to imply recommendation or endorsement by the National Institute of Standards and Technology, nor is it intended to imply that the materials or equipment identified are necessarily the best available for the purpose.

These opinions, recommendations, findings, and conclusions do not necessarily reflect the views or policies of NIST or the United States Government.

Why are reference materials important?

Reference materials help with:


- **Verifying instrument performance** - Ensure instruments work correctly
- **Validating and calibrating measurement systems** - Ensure that analysis is accurate across industries
- **Developing and quality controlling products** - Ensure products meet quality control standards
- **Standardizing reporting** - Ensure published studies are comparable across different assays, instruments, and labs
- **Estimating measurement uncertainty** – Quantify instrument sensitivity
- **Training purposes**

Particle-Based Reference Materials In Development **NIST**

RGTM 10231 silica-based

- Sub-micrometer ($< 1 \mu\text{m}$) particles with lower refractive index than typical polymer-based spheres
- Multi-modal sample covering wide size range


Benkstein et al. (2022) *J. Pharm Sci.* 111:699.



RM 8634 ETFE particles

- Subvisible proteinaceous particle surrogate
- Enables more accurate monitoring of particles in biotherapeutics


NIST Special Publication 260-193
[Available 2019](#)



RGTM 10237 liposome-based

- Test material relevant for characterization of lipid-based particles loaded with therapeutic vectors
- Development underway to examine material stability


Lehman et al. (2023) *Langmuir.* 39:12313.




SRM 1989 visible particles

- Visible particle standard reference materials certified for size (3 varieties)
- Uniform, non-spherical

NIST Special Publication 260-255
[Available 2025](#)




Development of The Visible Particle Standard



1. **Telikepalli S**, Gonzalez K, Dragulin-Otto S, Ripple D, Carrier M, Khan M. Development of protein-like reference material for semi-quantitatively monitoring visible proteinaceous particles in biotherapeutics. *PDA J Pharm Sci Technol*. 2019 Sep–Oct;73(5):418–432.
2. Narhi LO, Bou-Assaf GM, Gonzalez K, Mazaheri M, Messick SK, **Telikepalli SN**. Filling the pharmacopeial gaps of visual inspection: toward standardization and consistency of visible particle testing. *USP Pharm Forum*. 2021 May;47(3).
3. **Telikepalli SN**, Carrier MJ, Ripple DC, Barnett G, Bhirde A, Bolton D, Bou-Assaf GM, Ferrari E, Leigh S, Levitskaya-Seaman S, Menzen T, Nikels F, Riley A, Saggi M, Sahni N, Vernooij E, Wuchner K. An interlaboratory study to identify potential visible protein-like particle standards. *AAPS PharmSciTech*. 2022 Dec;24(1):18.
4. De Luna IF, **Telikepalli SN**, Carrier M, Ripple D, Srinivasan C, O'Connor T, Lute S, Bhirde A. Root cause analysis investigation of visible particulates in therapeutic protein drug product using morphologically directed Raman spectroscopy. *Sci Rep*. 2025 Nov;15:42026.
5. **Telikepalli SN**, Ripple DC, Carrier M, Steffens KL, Newton D, Montgomery C, Ritchie NWM, Asmar AJ, Halter M (2025) Certification of Standard Reference Materials® 1989: Monodisperse Irregularly Shaped Epoxy-Based Particles (Nominal 100 µm, 150 µm, 220 µm). (National Institute of Standards and Technology, Gaithersburg, MD), NIST Special Publication (SP) 260-255. <https://doi.org/10.6028/NIST.SP.260-255>.

Visible Particles

Visible particles is **one of the main reasons** for drug recall; 31 % of recalls from 2017 to 2024 were due to particulate contamination (FDA Recalls, Market Withdrawals, and Safety Alerts Database)¹




Vial containing VP

An image of a representative particle.


Non-proteinaceous:
not acceptable

Proteinaceous:
needs to be monitored & controlled



Ensure quality & manufacturing consistency

May affect safety of the drug



Instruments qualified with reference particulates & training sets

Industry trying to move towards automated methods & we are interested in supporting that

1. <https://www.fda.gov/drugs/drug-safety-and-availability/drug-recalls> and <https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/recalls-biologics>

Challenges with Visible *Proteinaceous* Particles **NIST**

Technical & Methodological Challenges

- **Subjective & non-quantitative:** No clear size cut-off for particle being visible to human eye
- **Visibility is \neq 100% detection:** probabilistic (ex: 150 μ m bead POD 70%, fibrillar particle might need to be a lot bigger)
- **Many parameters effect visual inspection** (operator, illumination, observation time, type & speed of rotation, fill volume & primary packaging, location of particulate—floating or stuck, **type of particle**—transparency, size, density, shape, etc.)

Regulatory & Standardization Gaps

- **Regulatory guidelines may be vague**
- **No commercial protein-like particle reference standards** for monitoring proteinaceous VP & for training
- **Company specific/ product specific limits & criteria**
- **No standard definition** of “visible” for irregular, translucent proteinaceous particles

Visible Particle Interlab Study


Visual Assessment of Particles in Biotherapeutic Products



Reference ETFE Particles



Visible Proteinaceous Particles



Reference SU-8 Particles



Participant's
Feedback

NIST Reference Material
Available to Industry

Qualitative study to get input from industry
Goal was to use feedback to develop a RM

List of participants in the study


Amgen, Inc.
AstraZeneca
Biogen
Boehringer Ingelheim Pharma GmbH
Coriolis Pharma
Eli Lilly and Company
Fibrogen
Food and Drug Administration
Genentech, Inc., Roche Group
GlaxoSmithKline
Janssen R&D, DPDS BioTDS Analytical Dev.
Macrogenics
Porton Biopharma Ltd
Sanofi, BioAnalytics

Production of the Two Particle Standards

ETFE Particles



Photolithographic Particles (SU-8)




1. Coat wafer with the release layer (Omnicat) followed by SU-8 2005

2. Expose wafer to UV light with noncontact exposure tool

3. Post exposure bake at 95°C


4. Remove unexposed SU-8 in developer solution

5. Dissolve Omnicat layer and release particles into solvent



Test kit for participant evaluation.


Considerations for Interlab Study



Two Standards - Two Applications for Visual Inspection

Designed 2 particle candidates: 1) mechanically produced ETFE (larger) 2) photolithographically produced SU-8

1) ETFE





Comments

Looked “more proteinaceous”
Polydisperse haze of proteinaceous particles in a vial

Applications

- Semi-Quant Use¹
- Formulation Dev
- Stability testing
- Qualification & Training

2) Photolithographically produced (SU-8)



Monodisperse,
distinct particles (150
or 250) μm

- Sensitivity of inspection
- POD studies
- Define “visible”
- Qualification & Training

¹Telikepalli S, et al. PDA J Pharm Sci Technol. 2019;73(5):418-32.

Applications based on their physical properties.

Each type of particle serves a different but complementary role in visual inspection practices

Interlab Comparison: Two Paths Forward

Overall Findings: 1) No perfect standard
2) Can't meet user need with a single RM
3) Both types could be useful for training purposes



Photolithographic (SU-8) Particles

Pros

- Used as **size** standard (irregular particles)
- More uniform
- Easier to characterize

Cons

- Harder to produce
- SU-8 not perfect mimic

- 100 μm , 150 μm , & 220 μm
- Certify for size, concentration
- 1 morphology (may expand later)

ETFE Particles

Pros


- Used as **conc.** standard (irregular particles)
- Semi-quant use favored
- Looks more like protein particles

Cons

- Harder to characterize
- Sizing limits harder to define


- 150 μm to 300 μm
- Certify for particle size distribution
- Details TBD

General Schematic for SRM 1989 Production



Fabrication of an Irregular Shaped Visible Particle

Step 1: Optimize Photolithographic Particles (SU-8) Production in the NIST Nanofab Facility (M. Carrier)



1. Coat wafer with the release layer (Omnicat) followed by SU-8 2005

2. Expose areas of wafer to UV light with noncontact exposure tool


3. Post exposure bake at 95°C to crosslink the UV exposed areas

4. Remove unexposed SU-8 in developer solution

5. Dissolve Omnicat layer and release particles into solvent

Solvent exchanges,
Purification,
etc.

Measurement Strategy for SRM 1989




NIST SP 260-255

Ensure 1) Consistency in methods 2) Batch homogeneity 3) Stability of size over time


The certified size & uncertainties characterized in more rigorous detail than probably required for user community.

Sizing of SRM 1989


1 unit of SRM 1989 contains 3 particle sizes (3 vials)



220 μm ABD or
335 μm MFD




150 μm ABD or
225 μm MFD




100 μm ABD or
150 μm MFD

Area Based
Diameter



Max Feret
Diameter



ABD - diameter of a circle with the same number of pixels as a particle in a binary image (equivalent to ECD).

MFD - maximum distance between two parallel planes touching a particle border but not intruding into the particle interior.

Certified dimensional values are traceable to the Standard Meter through the use of a NIST-calibrated stage micrometer, which provides a length reference that is traceable to the SI.


Apparent vs. Actual Size

Apparent Size (Optical)

- Based on optical image analysis (experimental)
- General Method: 1) Optically image particles on two optical microscopes; 2) Adjust for background and threshold; 3) Software to size particles
- ABD & MFD

Actual Size (True)

- True particle diameter
- Corrected for optical diffraction effects
- Higher accuracy representation
- ABD & MFD



For most applications, this differentiation is probably **NOT** important.

NIST Special Publication 260
NIST SP 260-255
**Certification of Standard Reference
Material[®] 1989**

Monodisperse Irregularly Shaped Epoxy-Based Particles
(Nominal 100 μm , 150 μm , 220 μm)

Srivalli N. Telikepalli
Dean C. Ripple
Michael Carrier
Kristen L. Steffens
David Newton
Christopher Montgomery
Nicholas W. M. Ritchie
Anthony J. Asmar
Michael Halter

This publication is available free of charge from:
<https://doi.org/10.6028/NIST.SP.260-255>

Standard Reference Material[®] 1989
Epoxy Based Monodisperse Photoresist Particles for
Particle Size and Morphology
CERTIFICATE OF ANALYSIS

Purpose: This Standard Reference Material (SRM) is intended primarily for use as a particle size standard to validate the precision of sizing methods of irregular shaped particles over an approximate size range of 100 μm to 220 μm . SRM 1989 has been developed to mimic the optical properties of visible aggregated proteinaceous particles.

Description: A unit of SRM 1989 comprises 3 vials, with each vial containing approximately 20 mL of an aqueous suspension of SU-8 photoresist particles in a solution of 0.02 % sodium azide and 0.01 % surfactant [4-(1,1,3,3-Tetramethylbutyl)phenyl-polyethylene glycol] by mass concentration. The SU-8 photoresist particles were prepared by fabrication of particles onto a sacrificial silicon wafer using a photolithographic process, followed by release from the wafer, purification, and dilution.

Certified Values: The certified particle size in Area Based Diameter (ABD) and Maximum Feret Diameter (MFD) and their related expanded uncertainties were measured on SRM 1989 through optical and electron microscopy methods. Area Based Diameter is the diameter of a circle whose area contains the same number of pixels as a particle in a binary image. Maximum Feret Diameter is the maximum distance between two parallel planes touching a particle border but not intruding in the particle interior. These certified dimensional values are traceable to the Standard Meter through the use of a NIST-calibrated stage micrometer, which provides a length reference that is traceable to the SI. Table 1 below reports both the Actual physical size (the true diameter of the particle) and the Apparent size of the particle, as determined by optical methods. The Apparent size is larger than the Actual size because of optical diffraction effects. Apparent size was measured on an optical microscope using Köhler illumination with green light (≈ 530 nm wavelength), a 0.30 numerical aperture objective, and particle edge defined as the perimeter where the image intensity is halfway between the background intensity and the darkest portion of the imaged particle border. Actual size was determined by correcting the Apparent size for optical diffraction effects.

Table 1. The certified Apparent and Actual Size, in Area Based Diameter (ABD) and Maximum Feret Diameter (MFD), of the 3 nominally sized particle suspensions that comprise 1 unit of SRM 1989.

Nominal Particle Size (μm)	Apparent ABD (μm) ^(a)	Actual ABD (μm) ^(a)	Apparent MFD (μm) ^(a)	Actual MFD (μm) ^(a)
100	100.65 \pm 2.15	98.38 \pm 2.20	149.11 \pm 1.37	147.69 \pm 1.40
150	150.16 \pm 2.21	147.92 \pm 2.30	223.08 \pm 1.51	221.76 \pm 1.55
220	222.39 \pm 2.14	219.76 \pm 2.20	333.33 \pm 1.66	331.67 \pm 1.74

SRM 1989 Quality



- **International recognition of quality:** Our QMS is formally approved by [Inter-American Metrology System \(SIM QSTF\)](#), confirming compliance with key ISO standards and validating the rigor of our SRM processes.

- **Enables global acceptance:** This approval is essential for recognition of Calibration and Measurement Capabilities (CMCs) under the [CIPM Mutual Recognition Arrangement](#), supporting worldwide comparability of measurement results.

- **Demonstrates excellence and traceability:** The certificate verifies our commitment to high-quality reference material production, strengthening confidence in our SRM portfolio and its metrological traceability.

Potential Applications of SRM 1989



Training of visual inspection analysts with regards to “protein-like” particles

Determining sensitivity of inspection/probability of detection studies

Qualification of semi-automated or automated methods

Status: Product released in 2025

Acknowledgements



Dean Ripple (retired)

Michael Carrier

Kristen Steffens

Christopher Montgomery

Kurt Benkstein

Sean Lehman

Wyatt Vreeland

Kyle Anderson

Dick Cavicchi

David Newton

Anthony Asmar

Michael Halter

Nicholas Ritchie

Z.Q. John Lu

Thank you!

snt2@nist.gov or
srivalli.telikepalli@nist.gov



Credit: J. Stoughton/NIST